EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of pitolisant in residual excessive daytime sleepiness for patients with obstructive sleep apnea adhering to continuous positive airway pressure therapy in the HAROSA studies: An individual patient meta-analytical approach

Dries Testelmans, Philippe Lehert, Jerryll Asin, Johan Imschoot, Christian Caussé, Jean-Louis Pépin

Sleep Medicine · 2025

DOI: 10.1016/j.sleep.2025.02.003 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Sleep Medicine, 2025. Verfasst von Dries Testelmans und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology, Leuven University Center for Sleep and Wake Disorders, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. E…. Hauptthemen laut MEDLINE: Continuous Positive Airway Pressure, Sleep Apnea, Obstructive, Disorders of Excessive Somnolence. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Fondation Université Grenoble Alpes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Obstructive sleep apnea (OSA) is typically treated with continuous positive airway pressure (CPAP) therapy. Some patients experience residual excessive daytime sleepiness (EDS) under CPAP. Pitolisant demonstrated effectiveness in reducing EDS. An individual patient meta-analysis was conducted assessing the efficacy and safety of pitolisant 20 mg and 40 mg versus placebo to treat EDS in patients with OSA using CPAP. METHODS: A study-patient, hierarchical, random-effects model was used. Epworth Sleepiness Scale (ESS) and Oxford Sleep Resistance test (OSLER) were co-primary endpoints. Secondary endpoints included EDS-Z scores, fatigue, clinical global impression, and quality of life (QoL). RESULTS: The searches identified three randomized controlled trials. Individual patient data were derived from 423 patients (placebo: n = 120, pitolisant 20 mg: n = 183, pitolisant 40 mg: n = 120). Treatment effects on ESS were -3.20 (95 % confidence interval [CI]: 4.37, -2.00; P < 0.001) and -3.57 (95 % CI: 4.87, -2.80); P < 0.001) for the 20 mg and 40 mg doses, with corresponding standardized mean differences (SMD) of -0.71 (95 % CI: 0.45, -0.97) and -0.79 (95 % CI: 0.51, -1.08). Treatment effects in minutes for OSLER were 1.24 (95 % CI: 0.60, 1.10, SMD = 0.61; P = 0.001) and 1.21 (95 % CI: 0.06, 1.38, SMD = 0.51; P = 0.006). Pitolisant 40 mg was superior to the 20-mg dose for older age (≥50 years) and higher baseline apnea-hypopnea index values (≥15). No significant differences were observed for safety outcomes. CONCLUSION: Pitolisant 20 mg and 40 mg were significantly therapeutically superior to placebo in treating residual EDS in patients with OSA who received CPAP on the outcomes for ESS, OSLER, and QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Continuous Positive Airway PressureSleep Apnea, ObstructiveDisorders of Excessive SomnolenceHumansQuality of LifeTreatment OutcomeRandomized Controlled Trials as TopicMiddle AgedMalePiperidines

Stichwörter der Autor:innen

Continuous positive airway pressureObstructive sleep apneaPitolisantQuality of lifeResidual excessive daytime sleepiness

Substanzen

pitolisantPiperidines

Autor:innen und Institutionen

  • Department of Pneumology, Leuven University Center for Sleep and Wake Disorders, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. Electronic address: dries.testelmans@uzleuven.be.
  • University of Melbourne, Parkville VIC, 3052, Australia; Université Catholique de Louvain, Pl. de L'Université 1, 1348, Ottignies-Louvain-la-Neuve, Belgium. Electronic address: Philippe.lehert@gmail.com.
  • Department of Pulmonary Medicine, Centre for Sleep Medicine, Amphia Hospital, Molengracht 21, 4818 CK Breda, Netherlands. Electronic address: JAsin@Amphia.nl.
  • Transmedica, Geraardsbergsesteenweg 12, 9320 Aalst, Belgium. Electronic address: J.Imschoot@bioprojet.be.
  • Bioprojet Pharma, 9 Rue Rameau, 75002 Paris, France. Electronic address: c.causse@bioprojet.com.
  • HP2 Laboratory, Inserm U1300, Grenoble Alpes University, CHU Michallon, 38043, Grenoble, France. Electronic address: JPepin@chu-grenoble.fr.

Förderung

  • Agence Nationale de la Recherche
  • Fondation Université Grenoble Alpes

Zitieren

APA

Testelmans, D., Lehert, P., Asin, J., Imschoot, J., Caussé, C., & Pépin, J. L. (2025). Efficacy and safety of pitolisant in residual excessive daytime sleepiness for patients with obstructive sleep apnea adhering to continuous positive airway pressure therapy in the HAROSA studies: An individual patient meta-analytical approach. Sleep Medicine. https://doi.org/10.1016/j.sleep.2025.02.003

Vancouver

Testelmans D, Lehert P, Asin J, Imschoot J, Caussé C, Pépin JL. Efficacy and safety of pitolisant in residual excessive daytime sleepiness for patients with obstructive sleep apnea adhering to continuous positive airway pressure therapy in the HAROSA studies: An individual patient meta-analytical approach. Sleep Medicine. 2025. doi:10.1016/j.sleep.2025.02.003

BibTeX
@article{Testelmans2025,
  author = {Testelmans, Dries and Lehert, Philippe and Asin, Jerryll and Imschoot, Johan and Caussé, Christian and Pépin, Jean-Louis},
  title = {Efficacy and safety of pitolisant in residual excessive daytime sleepiness for patients with obstructive sleep apnea adhering to continuous positive airway pressure therapy in the HAROSA studies: An individual patient meta-analytical approach},
  journal = {Sleep Medicine},
  year = {2025},
  doi = {10.1016/j.sleep.2025.02.003}
}
Kostenlos starten →